Global Skeletal Dysplasia Market: Overview
Skeletal dysplasia is a rare disease with more than 450 types. It is also widely known as osteochondrodysplasias. It affects the growth and development of the bone and cartilage. The level of severity of this disorder varies from neonatal lethality to growth differences experienced in adulthood. Skeletal dysplasia is difficult to diagnosis, as it is a rare disorder. However, certain symptoms include slow growth, deformities in large head, short upper arms or thighs, curved bones, arthritis or joint pain, and others. The condition is highly prevalent in children and early diagnosis helps creating awareness. This condition is a result of defective genes, which are either inherited from parents or mutated during the development of fetus. The defective gene is extremely difficult to identify. Hence, companies are making significant investments in research & development of treatment for this rare disease.
Global Skeletal Dysplasia Market: Key Trends
Rise in awareness and early diagnosis of skeletal dysplasia drive the global skeletal dysplasia market. Technological advancements is another factor anticipated to propel the global market in the next few years. Key players are investing in the development of the treatment for this condition. Moreover, prevalence of skeletal dysplasia in children is increasing. These factors are expected to drive the global market. However, less awareness about skeletal dysplasia and poor diagnosis hamper the growth of the global market, especially in developing regions.
According to a journal published on UpToDate, prevalence of skeletal dysplasia is estimated to be 2.4 per 100,000 births globally every day. The prevalence of skeletal dysplasia estimated during pregnancy is 7.5 per 100,000 women screened through ultrasound. It is a rare disease; however, there are 450 different forms of skeletal dysplasia. Patients with this condition undergo extensive medical and surgical treatments throughout childhood and adulthood.
Global Skeletal Dysplasia Market: Segmentation
The global skeletal dysplasia market can be segmented based on type, treatment, end-user, and region. In terms of type, the market can be classified into achondroplasia, hypochondroplasia, thanatophoric dysplasia, osteogenesis imperfect, and others. Achondroplasia is the most common type of skeletal dysplasia. According to research, prevalence rate of achondroplasia is 5 in 100,000 and incidence is 1 in 20,000 live births. Based on treatment, the global skeletal dysplasia market can be categorized into medication, surgery, and others. There is no cure for the disorder; however, treatments are recommended for orthopedic and medical conditions caused by skeletal dysplasia. Medications include growth hormones, muscle relaxants, parathyroid hormones, and others. Surgical options include inserting drainage tubes to avoid chronic ear infections, tracheotomy, widening spinal canal process, and correcting physical deformities. In terms of end-user, the market can be divided into hospitals, ambulatory surgical centers, and others.
Global Skeletal Dysplasia Market: Regional Analysis
In terms of region, the global skeletal dysplasia market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2018, and the trend is projected to continue during the forecast period. This is due to rise in awareness about the treatment of orthopedic and medical problems, increase in health care expenditure, and presence of key players involved in the clinical trials for development of therapies to cure skeletal dysplasia. Moreover, advanced health care facilities, awareness about early diagnosis, and recognition of orphan drugs by governments boost the growth of the skeletal dysplasia market in the U.S. According to research, the estimated prevalence of this rare bone disease is 1 in 1,600. In Europe, the rare disease affects a small population. It affects 30 million people, of which 6,800 have been identified. The skeletal dysplasia market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period. Prevalence of rare disorders including skeletal dysplasia, early diagnosis, and prevalence in children are the factors fueling the growth of the market in the region. Expansion of national and international collaborations and technological advancements are expected to augment the skeletal dysplasia market in Asia Pacific.
Currently, there are no therapies for skeletal dysplasia. Major companies involved in the development of therapies in clinical trials include BioMarin Pharmaceuticals, Clementia Pharmaceuticals, Regeneron Pharmaceuticals, Ultragenyx Pharmaceutical, and Alexion Pharmaceuticals.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.